Posted by Michael Wonder on 02 Sep 2020
EMA receives application for marketing authorisation of Dexamethasone Taw for COVID-19
2 September 2020 - EMA has started evaluating an application for the authorisation of Dexamethasone Taw for treating hospitalised adult patients with COVID-19.
The application, from Taw Pharma, will be evaluated by EMA’s human medicines committee (CHMP) according to an accelerated assessment timetable.
This will enable the CHMP to issue an opinion on the benefits and risks of Dexamethasone Taw within the shortest possible timeframe.
